WS #15765
UnitedHealth Group and Johnson & Johnson both delivered strong Q3 results, beating earnings estimates and raising full-year guidance. UnitedHealth's rise was driven by lower-than-expected costs, while J&J's beat was supported by cost controls and strong pharmaceutical sales, despite a one-time charge for talc litigation. This performance reinforces the defensive nature of the healthcare sector, attracting capital as investors seek stability amid broader market uncertainty and geopolitical risks.
Healthcare Defensive Strength
UnitedHealth Group and Johnson & Johnson both delivered strong Q3 results, beating earnings estimates and raising full-year guidance. UnitedHealth's rise was driven by lower-than-expected costs, while J&J's beat was supported by cost controls and strong pharmaceutical sales, despite a one-time charge for talc litigation. This performance reinforces the defensive nature of the healthcare sector, attracting capital as investors seek stability amid broader market uncertainty and geopolitical risks.